The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia

It is of urgent need to understand the safety and effectiveness of novel coronavirus (COVID-19)-inactivated vaccine in patients with hyperlipidemia (HLD). However, data on the safety and immune response of SARS-CoV-2-inactivated vaccine in HLD patients are limited. In this prospective study, 105 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lei, Liu, YaMing, Guo, Qiao, Jiang, DePeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487380/
https://www.ncbi.nlm.nih.gov/pubmed/37693840
http://dx.doi.org/10.1515/med-2023-0780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487380/
https://www.ncbi.nlm.nih.gov/pubmed/37693840
http://dx.doi.org/10.1515/med-2023-0780

Ejemplares similares